Envista Holdings reports annual meeting results

Envista Holdings Corp (NYSE:NVST), a dental equipment and supplies company with a market capitalization of $3.19 billion, disclosed the outcomes of its 2025 Annual Meeting of Stockholders in a recent 8-K filing with the Securities and Exchange Commission. According to InvestingPro analysis, the company is currently undervalued, making it an interesting watch for value investors tracking the healthcare sector. The meeting, which took place on Monday, June 10, 2025, covered several key proposals including the election of directors, ratification of the company’s independent auditor, and executive compensation.

Stockholders re-elected all director nominees for a one-year term expiring at the company’s 2026 annual meeting. The directors elected include Paul Keel, Wendy Carruthers, Kieran Gallahue, Scott Huennekens, Barbara Hulit, Vivek Jain, Daniel Raskas, and Christine Tsingos. The vote counts ranged from 153,111,918 votes in favor for Scott Huennekens to 163,391,468 for Paul Keel, with withheld votes and broker non-votes also reported.

Additionally, the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the year ending December 31, 2025, was ratified with an overwhelming majority of 165,698,453 votes in favor.

The stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers with 154,290,359 votes for, 9,339,610 against, and 64,812 abstentions. Broker non-votes tallied 2,120,352. While the company maintains a moderate debt level and strong liquidity position with a current ratio of 2.12, InvestingPro data shows it operates with good financial health, receiving an overall score of 2.57 out of 5.

Furthermore, an amendment to Envista Holdings’ Omnibus Incentive Plan was approved to increase the number of shares authorized for issuance under the plan by 6,425,000 shares. The proposal received 154,113,806 votes for, 9,487,296 against, and 93,679 abstentions, with broker non-votes again at 2,120,352.

The 8-K filing also included the cover page interactive data file, which is embedded within the Inline XBRL document. This filing provides a transparent view of the company’s governance and executive compensation approach, reflecting the stockholders’ support for the current direction of the company.

The information in this article is based on Envista Holdings Corp’s SEC filing. Looking ahead, the company is scheduled to report its next earnings on July 30, 2025, with analysts expecting a return to profitability this year. For deeper insights into Envista’s financial health and growth prospects, including 6 additional ProTips and comprehensive valuation metrics, check out the detailed Pro Research Report available on InvestingPro.

In other recent news, Envista Holdings Corp reported its first-quarter 2025 earnings, surpassing analysts’ expectations with an adjusted earnings per share (EPS) of $0.24, compared to the forecasted $0.21. The company’s revenue also exceeded projections, reaching $617 million against an anticipated $609.5 million. Envista Holdings has maintained its guidance for 2025, projecting 1% to 3% core growth despite challenges such as unfavorable currency exchange rates. In a separate development, Baird analysts upgraded Envista Holdings from Neutral to Outperform, raising the price target to $23.00 from $21.00. This decision reflects confidence in the company’s new leadership and strategic initiatives. The upgrade was influenced by findings from Baird’s domestic dental survey, which pointed to improvements in the industry. Envista’s management has been credited with stabilizing the company’s position in the competitive dental market. These recent developments indicate a positive outlook for Envista Holdings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.